cadonilimab
akesobio
['cadonilimab', 'ak104', 'akeso']
akeso announces oral presentation featuring promising clinical data of cadonilimab (pd-1/ctla-4 bsabs, ak104) for the first-line treatment of r/m cervical cancer at asco 2022 #stocksmarket #pressrelease
Join us at https://t.co/9QZSYoqhvl - Stock Market News and Press Releases. #StockMarket - As an affiliate, we earn from qualifying purchases.